CLINICAL TRIALS PROFILE FOR MINOCIN
✉ Email this page to a colleague
All Clinical Trials for MINOCIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00240513 ↗ | Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin | Terminated | Stiefel, a GSK Company | Phase 4 | 2004-08-01 | The use of oral antibiotics alone to treat inflammatory acne provides little to no long term therapeutic benefit. Acne relapse rates can be reduced by using topical tretinoin 0.01% in conjunction with minocycline, thereby increasing the therapeutic effect of the oral antibiotic. |
| NCT00240513 ↗ | Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin | Terminated | Derm Research @ 888 Inc. | Phase 4 | 2004-08-01 | The use of oral antibiotics alone to treat inflammatory acne provides little to no long term therapeutic benefit. Acne relapse rates can be reduced by using topical tretinoin 0.01% in conjunction with minocycline, thereby increasing the therapeutic effect of the oral antibiotic. |
| NCT00355459 ↗ | A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease | Withdrawn | University of Texas Southwestern Medical Center | N/A | 2005-08-01 | The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland secretions) characteristics in patients with chronic Blepharitis and associated dry eyes. |
| NCT00456677 ↗ | Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma | Completed | State University of New York - Downstate Medical Center | Phase 2 | 1996-06-01 | Trial of effects of minocycline as "add-on" therapy to adults with asthma with a history of requiring at least one episode of oral steroid therapy to control the disease. |
| NCT00473083 ↗ | Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer | Completed | Hoffmann-La Roche | Phase 2 | 2009-01-01 | The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MINOCIN
Condition Name
Clinical Trial Locations for MINOCIN
Trials by Country
Clinical Trial Progress for MINOCIN
Clinical Trial Phase
Clinical Trial Sponsors for MINOCIN
Sponsor Name
